Literature DB >> 25843053

Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep.

Pit J Voss1, Martin J Stoddart2, Anke Bernstein3, Rainer Schmelzeisen4, Katja Nelson5, Vincent Stadelmann6, Thomas Ziebart7, Philipp J Poxleitner8,9.   

Abstract

OBJECTIVES: Bisphosphonate-related osteonecrosis of the jaw (BP-ONJ) occurs in 1 % of patients with medication-induced osteoporosis treated with bisphosphonates. Sheep are an established large animal model for investigating osteoporotic skeletal changes. Zoledronate significantly reduces tissue mineral variability in ovariectomized sheep. The aim of this study was to analyze bone healing after tooth extraction in sheep with induced osteopenia and zoledronate administration.
MATERIALS AND METHODS: Eight adult ewes were randomly divided into two groups of four animals. All sheep underwent ovariectomy and a low-calcium diet. Dexamethasone was administered weekly for 16 weeks. Zoledronate was then given every third week for a further 16 weeks in four sheep; these infusions were repeated after extraction of two lower premolars. Four sheep without zoledronate administrations served as controls.
RESULTS: Due to general health conditions, two sheep of the zoledronate group had to be excluded before surgery. The remaining two sheep of this group developed BP-ONJ lesions at the extraction site and various other sites in both jaws. Control group animals showed uneventful wound healing. Histology of the alveolar processes as well as lumbar spine revealed larger portions of old bone and smaller portions of new bone in the zoledronate group.
CONCLUSIONS: This animal study showed uneventful wound healing after tooth extraction in osteopenic sheep whereas zoledronate treatment leads to development of BP-ONJ-like lesions. CLINICAL RELEVANCE: As bisphosphonate administration is a standard treatment for glucocorticoid-induced osteoporosis, this model can be used for further research in pathogenesis and management of bisphosphonate-related adverse events.

Entities:  

Keywords:  Bisphosphonates; Large animal study; Oral and maxillofacial surgery; Oral pathology; Osteoporosis; Ovariectomy; Wound healing

Mesh:

Substances:

Year:  2015        PMID: 25843053     DOI: 10.1007/s00784-015-1468-6

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  35 in total

1.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

2.  Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.

Authors:  C C Glüer; K E Scholz-Ahrens; A Helfenstein; G Delling; W Timm; Y Açil; R Barkmann; J Hassenpflug; B Stampa; F Bauss; J Schrezenmeir
Journal:  Bone       Date:  2006-12-15       Impact factor: 4.398

3.  Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate.

Authors:  D Wen; L Qing; G Harrison; E Golub; S O Akintoye
Journal:  Oral Dis       Date:  2010-12-02       Impact factor: 3.511

4.  Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.

Authors:  Orlaith Brennan; Oran D Kennedy; T Clive Lee; Susan M Rackard; Fergal J O'Brien
Journal:  J Orthop Res       Date:  2010-09-30       Impact factor: 3.494

5.  Relationship between bisphosphonate concentration and osteoclast activity and viability.

Authors:  D J Rowe; L A Etre; M J Lovdahl; D J Pietrzyk
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Jul-Aug       Impact factor: 2.416

6.  A sheep model for fracture treatment in osteoporosis: benefits of the model versus animal welfare.

Authors:  M Egermann; J Goldhahn; R Holz; E Schneider; C A Lill
Journal:  Lab Anim       Date:  2008-09-09       Impact factor: 2.471

7.  Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.

Authors:  Babul Borah; Thomas E Dufresne; Paula A Chmielewski; Gary J Gross; Marla C Prenger; Roger J Phipps
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

8.  Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.

Authors:  Stephen T Sonis; Brynmor A Watkins; Gregory D Lyng; Mark A Lerman; Kenneth C Anderson
Journal:  Oral Oncol       Date:  2008-08-19       Impact factor: 5.337

9.  Does dental and oral health influence the development and course of bisphosphonate-related osteonecrosis of the jaws (BRONJ)?

Authors:  Michael Krimmel; Jana Ripperger; Martin Hairass; Sebastian Hoefert; Susanne Kluba; Siegmar Reinert
Journal:  Oral Maxillofac Surg       Date:  2013-03-20

10.  Bisphosphonate related osteonecrosis of the jaw: A minipig large animal model.

Authors:  Christoph Pautke; Kilian Kreutzer; Jochen Weitz; Martina Knödler; Daniela Münzel; Gabriele Wexel; Sven Otto; Alexander Hapfelmeier; Stephen Stürzenbaum; Thomas Tischer
Journal:  Bone       Date:  2012-05-07       Impact factor: 4.398

View more
  7 in total

1.  The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay.

Authors:  A M Pabst; M Krüger; K Sagheb; T Ziebart; C Jacobs; S Blatt; E Goetze; C Walter
Journal:  Clin Oral Investig       Date:  2016-05-12       Impact factor: 3.573

2.  Evaluation of BP-ONJ in osteopenic and healthy sheep: comparing ZTE-MRI with µCT.

Authors:  Pit Voss; Ute Ludwig; Philipp Poxleitner; Veronika Bergmaier; Nora El-Shafi; Dominik von Elverfeldt; Vincent Stadelmann; Jan-Bernd Hövener; Tabea Flügge
Journal:  Dentomaxillofac Radiol       Date:  2016-02-05       Impact factor: 2.419

Review 3.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

Review 4.  Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.

Authors:  Henrik Holtmann; Julian Lommen; Norbert R Kübler; Christoph Sproll; Majeed Rana; Patrick Karschuck; Rita Depprich
Journal:  J Int Med Res       Date:  2018-08-09       Impact factor: 1.671

Review 5.  Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency.

Authors:  Luca Dalle Carbonare; Monica Mottes; Maria Teresa Valenti
Journal:  Nutrients       Date:  2021-02-08       Impact factor: 5.717

Review 6.  Is the Use of Bisphosphonates Putting Horses at Risk? An Osteoclast Perspective.

Authors:  Fernando B Vergara-Hernandez; Brian D Nielsen; Aimee C Colbath
Journal:  Animals (Basel)       Date:  2022-07-03       Impact factor: 3.231

7.  Role of Periapical Diseases in Medication-Related Osteonecrosis of the Jaws.

Authors:  Nian Jing Rao; Jing Yi Wang; Ru Qing Yu; Yiu Yan Leung; Li Wu Zheng
Journal:  Biomed Res Int       Date:  2017-10-04       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.